GH secretagogue
CJC-1295 / Ipamorelin
mod-GRF(1-29) · NNC 26-0161
Most-searched peptide COMBINATION; the default GH-optimization stack in clinics and biohacking.
Evidence
Bhuman trials
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
GH secretagogue
Route
Subcutaneous
Demand rank
#7 most-searched
01Dosing & Protocol
Typical · reference only
Ipamorelin 200-300 mcg + CJC-1295 no-DAC 100 mcg per dose, pre-bed, 5-on/2-off (no-DAC daily; DAC weekly 1-2 mg)
Titration
Reconstitution — illustrative, not a recommendation
Pre-blend 20 mg (10+10) + 3 mL BAC = 3.33 mg/mL each; 200 mcg each = 6 U on U-100. Confirm DAC vs no-DAC (changes frequency ~7x).
Reconstitution calculatorlive tool
39units
on a U-100 syringedraw to the 39 mark
Concentration3.33 mg/mL
Draw volume0.39 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. FDA flagged immunogenicity/anaphylaxis risk. Health Canada advisory Apr 2026.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 (Sept 2024 + 2026 wave)
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows
Phase I PK/PD per component only; the combo & long-term outcomes are animal/anecdotal. Both are abandoned pharma assets (ipamorelin failed Phase II ileus; CJC-1295/DAC halted after a trial death). Zero outcome RCTs for the combo.
04Safety
Contraindications
- Active/recent cancer (GH/IGF-1 pro-proliferative)
- Pituitary/hypothalamic diseasehard stop
- Pregnancyhard stop
- Uncontrolled diabetes
- Active proliferative diabetic retinopathy
Key interactions
- Insulin/antidiabetics (GH lowers insulin sensitivity)
- Corticosteroids & somatostatin/octreotide (blunt GH response)
Serious signals
- FDA immunogenicity/anaphylaxis warning
- Ipamorelin IV death risk
- CJC-1295 vasodilation/HR rise
Monitoring
IGF-1 (titrate within age/sex range), fasting glucose/HbA1c.
05Related in GH secretagogue
06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
Peer-reviewedJCEM Teichman 2006Evidence — peer-reviewed studyHow we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high